Literature DB >> 16213416

BiTEs: bispecific antibody constructs with unique anti-tumor activity.

Evelyn Wolf1, Robert Hofmeister, Peter Kufer, Bernd Schlereth, Patrick A Baeuerle.   

Abstract

Bispecific T-cell engager molecules (BiTEs) constitute a class of bispecific single-chain antibodies for the polyclonal activation and redirection of cytotoxic T cells against pathogenic target cells. BiTEs combine a unique set of properties that have not yet been reported for any other kind of bispecific antibody construct, namely extraordinary potency and efficacy against target cells at low T-cell numbers without the need for T-cell co-stimulation. Here we review novel insights into the mechanism of BiTE action, which help to explain the unique features of BiTEs, as well as data from various animal models demonstrating the outstanding therapeutic potential of BiTEs for the treatment of malignant diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16213416     DOI: 10.1016/S1359-6446(05)03554-3

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  84 in total

Review 1.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

2.  Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.

Authors:  Joshua M Donaldson; Cindy Zer; Kendra N Avery; Krzysztof P Bzymek; David A Horne; John C Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

Review 3.  Are BiTEs the "missing link" in cancer therapy?

Authors:  Carter M Suryadevara; Patrick C Gedeon; Luis Sanchez-Perez; Terence Verla; Christopher Alvarez-Breckenridge; Bryan D Choi; Peter E Fecci; John H Sampson
Journal:  Oncoimmunology       Date:  2015-04-30       Impact factor: 8.110

Review 4.  Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

Authors:  Patrick Chames; Daniel Baty
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

5.  Molecular assembly for high-performance bivalent nucleic acid inhibitor.

Authors:  Youngmi Kim; Zehui Cao; Weihong Tan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-08       Impact factor: 11.205

6.  Toxicity Induced by a Bispecific T Cell-Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice.

Authors:  Claire Godbersen-Palmer; Tiffany A Coupet; Zakaria Grada; Samuel C Zhang; Charles L Sentman
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

7.  Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.

Authors:  Carolin Sellmann; Achim Doerner; Christine Knuehl; Nicolas Rasche; Vanita Sood; Simon Krah; Laura Rhiel; Annika Messemer; John Wesolowski; Mark Schuette; Stefan Becker; Lars Toleikis; Harald Kolmar; Bjoern Hock
Journal:  J Biol Chem       Date:  2016-09-30       Impact factor: 5.157

Review 8.  Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Authors:  Anupama Doraiswamy; Mansi R Shah; Rajat Bannerji
Journal:  Curr Hematol Malig Rep       Date:  2021-02-22       Impact factor: 3.952

Review 9.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

10.  Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.

Authors:  Daniel A Vallera; Bin Zhang; Michelle K Gleason; Seunguk Oh; Louis M Weiner; Dan S Kaufman; Valarie McCullar; Jeffrey S Miller; Michael R Verneris
Journal:  Cancer Biother Radiopharm       Date:  2013-04-23       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.